Inter Parfums
This article was originally published in The Rose Sheet
Executive Summary
Net sales in Q4 were $65.5 mil., representing growth of about 3%, or 9% at comparable foreign currency exchange rates, Inter Parfums announces Jan. 17. For the year, net revenues were up 16% to $273.4 mil. At comparable foreign currency exchange rates, sales increased nearly 17%, company adds. Inter Parfums also affirms 2006 guidance, with net sales expected to grow 10% to approximately $301 mil., and net income projected to rise 16% to $16.9 mil. Company notes guidance assumes the dollar remains at current levels. Growth in the year will stem largely from "ambitious" product launch initiatives (1"The Rose Sheet" May 16, 2005, p. 5). Inter Parfums will release operating results for the 2005 fourth quarter around March 7...
You may also be interested in...
Burberry, Lanvin Scents Lead “Ambitious” Inter Parfums Pipeline In ’06
A new Burberry fragrance family and a Lanvin scent for women will headline an aggressive product launch initiative in 2006, Inter Parfums CEO Jean Madar said during a May 11 analyst call
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.